1. General overview {#s0005}
===================

Genome-wide association studies (GWASs) are based on the screening of many genomes to find genetic variants associated with a trait or disease. Both dichotomous and quantitative traits can be analyzed in GWASs, and the genomes can be those of unrelated subjects or derive from samples with familiar structure (e.g., parent-affected child trios). Because GWASs analyze variants distributed throughout the genome, they are unbiased with respect to prior biological knowledge, offering the potential to identify novel variants and genes associated to the trait of interest.

The first small-scale GWAS results were performed in 2005--2006 and investigated age-related macular degeneration, a common disease in elderly populations worldwide ([@bb0255]; [@bb0580]). After those early efforts, the Wellcome Trust Case Control Consortium large-scale study in 2007 ([@bb1220]) gave way to the GWAS era. In recent years, hundreds of GWASs have been published. Their results are stored in a dedicated database, the GWAS Catalog, presently hosted by the EMBL-EBI ([https://www.ebi.ac.uk/gwas/](https://www.ebi.ac.uk/gwas){#ir0010}) ([@bb0720]). As of April 24th 2017, the catalog comprised 2880 studies and \> 9700 unique variant-trait associations. This figure refers to associations with a *p* value lower than or equal to 5 × 10^− 8^, which is usually considered as the threshold for genome-wide significance.

We mined the catalog to obtain a global overview of the application of GWAS in the field of infectious diseases. We classified studies and associations in broad categories depending on the disease or trait they analyzed. The category "infectious disease" was intended in a very broad sense: for instance, it included virus-associated cancers, specific phenotypes associated with infections (e.g., mood disorders in prion disease), and hematological measurements related to infectious agents (e.g., antibody levels for common infections, cytokine production during septic shock). We also defined categories for response to therapy, by classifying GWAS that analyzed the response to treatments for infectious diseases, non-communicable conditions, and vaccines. Overall, 4%, 0.66%, and 0.31% of all studies in the catalog were classified in the categories "infectious disease", "response to treatment for infectious disease", and "response to vaccine", respectively ([Fig. 1](#f0005){ref-type="fig"} ). In terms of unique variant-trait associations, percentages were as follows: 2.5% for "infectious disease", 0.18% for "response to treatment for infectious disease", and 0.66% for "response to vaccine" ([Fig. 1](#f0005){ref-type="fig"}). Based on the relative number of studies and associations, it is clear that some traits/diseases have attracted huge efforts that provided consequent reward (e.g., inflammatory/autoimmune disorders, metabolic traits and phenotypes), whereas others have been deeply investigated with comparatively modest success (e.g., neurologic/neuropsychiatric/cognitive diseases and traits, cancers). The reasons for these differences are manifold and outside the scope of this Review, which focuses on infections and related traits. Based on the percentages given above and on the comparison with other traits, we conclude that, despite the huge burden that infections pose for human health, relatively few GWASs for infectious diseases have been performed and these have attained a moderate success. Apparently, the best performance was obtained by GWASs for response to vaccination, with 9 studies that reported 64 associations. However, most of these associations will require validation, as they derive from a relatively small-scale study with no replication ([@bb0540]). Fig. 1Bar-plot representation of studies and associations recorded in the GWAS Catalog (as of April 24th, 2017). Bars represent the number of studies (red) or the number of unique SNP-trait associations (gray). Studies were manually categorized based on the diseases or trait they investigated. Only a subset of traits/diseases are shown. Associations were included only if they displayed an association *p* value ≤ 5 × 10^− 8^.Fig. 1Table 1Significant associations with infectious diseases (or related traits) in genome-wide association studies.Table 1**Pathogen/diseaseYearPopulationAssociated lociTrait descriptionReferencesGWAS for infectious diseases** **Viruses** ***Dengue virus***2011Asian ancestry\
Vietnam*MICB*, *PLCE1*Dengue shock syndrome (DSS) susceptibility([@bb0565]) **Diarrhoeal disease**2016European ancestry\
*Discovery:* Netherlands, UK, Spain, Germany\
*Replication:* Norway, UK, U.S., Germany, Netherland, Spain*NTN5*, *SEC1P*, *FUT2*Susceptibility to diarrhoeal disease in young children (1 and 2 years)([@bb0130]) ***Epstein-Barr virus (EBV)***2013Hispanic ancestry\
*Discovery:* Mexico\
*Replication:* Mexico*HLA-DRB1*, *HLA-DQB1*EBV seroreactivity measured by Epstein-Barr virus nuclear antigen 1 (anti-EBNA-1) titer([@bb1000]) ***Hepatitis B virus (HBV)***2009Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan and Thailand*HLA-DPB1*Chronic hepatitis B (CHB) susceptibility([@bb0520])2010Asian ancestry\
*Discovery:* China\
*Replication:* China*UBE4B*, *KIF1B*, *PGD*HBV-related hepatocellular carcinoma (HCC) susceptibility([@bb1265])2011Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*HLA-DPA1*, *HLA-DPB1*, *HLA-DQB1*, *HLA-DQB2*CHB susceptibility([@bb0810])2011Asian ancestry\
China*GRIN2A*HBV progression([@bb0695])2012Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan and Korea*HLA-DPA1*, *HLA-DPB1*HBV clearance([@bb0885])2012Asian ancestry\
*Discovery:* China\
*Replication:* China*GRIK1*, *HLA-DRB1*, *HLA-DQA1*HBV-related HCC([@bb0660])2013Asian ancestry\
*Discovery:* China\
*Replication:* China*STAT4*, *HLA-DQ*HBV-related HCC([@bb0500])2013Asian ancestry\
*Discovery:* Korea\
*Replication:* Korea*HLA-DP*, *HLA-DQ*, *EHMT2*, *TCF19*CHB susceptibility([@bb0570])2013Asian ancestry\
*Discovery:* China\
*Replication:* China*HLA-DQB2*, *HLA-C*, *UBE2L3*CHB susceptibility([@bb0450])2014Asian ancestry\
*Discovery:* China\
*Replication:* China*HLA-DQA2*, *HLA-DQB2*, *HLA-DPB1*, *HLA-DPA3*CHB in males([@bb0155])2015Asian ancestry\
*Discovery:* China\
*Replication:* China*HLA-C*, *CFB*, *NOTCH4*, *HLA-DOA*, *CD40*, *HLA-DQB1*, *HLA-DQB2*, *HLA-DPA1*, *HLA-DPB1*CHB susceptibility([@bb0505])2016Asian ancestry\
*Discovery:* China\
*Replication:* Chinars7000921 (locus 8p21.3)CHB susceptibility([@bb0665])2017[a](#tf0005){ref-type="table-fn"}Asian ancestry\
*Discovery:* China\
*Replication:* China*HLA-DR*HCV-related acute-on-chronic liver failure (ACLF) susceptibility([@bb1115]) ***Hepatitis C virus (HCV)***2010European ancestry\
Germany, Switzerland*IFNL2* (previously known as *IL28A*), *IFNL3/IFNL4*, *IFNL1* (previously known as *IL29*)Chronic hepatitis C (CHC) susceptibility([@bb0990])2011Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*HLA-DQ*, *HLA-DR*, *MICA*HCV-related HCC([@bb0615])2011Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*DEPDC5*HCV-related HCC([@bb0845])2012European ancestry\
*Discovery:* France, Switzerland\
*Replication:* France, Germany, Italy, UK, U.S., Australia*RNF7*, *MERTK*Liver fibrosis progression related to HCV infection([@bb0935])2013Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*C6orf10*, *BTNL2*, *BTNL2-HLA-DRA*CHC-induced liver cirrhosis (LC)([@bb1180])2013European, African and Afro-Caribbean ancestry\
*Discovery:* Austria, France, Germany, Greece, UK, U.S.\
*Replication:* U.S., Egypt*IFNL4*, *HLA-DQ*Spontaneous resolution of HCV infection([@bb0265])2013Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*HLA-DQB1*, *HLA-DQA1*CHC susceptibility([@bb0850])2014European ancestry\
*Discovery:* U.S., France, UK, Italy\
*Replication:* U.S., France, Italy*HLA-DQA1*, *HLA-DRB1*, *NOTCH4*Susceptibility to mixed cryoglobulinemia related to CHC([@bb1275])2017Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*TLL1*HCC development after HCV eradication([@bb0780]) **HCV and HIV co-infection**2016European ancestry\
France*OXTR*, *MAP1LC3BP1*Liver fibrosis progression([@bb1170]) ***Varicella Zooster virus (VZV)***2015European, African, Hispanic ancestry\
U.S.*HCP5*, *HLA-B*, *DHFR*Herpes zoster susceptibility([@bb0225]) ***Human Immunodeficiency Virus (HIV)***2007European ancestry\
*Discovery:* Denmark, Italy, Spain, Switzerland, Australia\
*Replication:* Denmark, Italy, Spain, Switzerland, Australia*HCP5*, *HLA-CHIV-1* viral load at set pointHIV-1 viral load at set point([@bb0300])2009European ancestry\
*Discovery:* France\
*Replication:* Denmark, Italy, Spain, Switzerland, Australia*HCP5*Progression to AIDS([@bb0670])2009European ancestry\
U.S.*HCP5*, *HLA-B*, *HLA-C*HIV-1 viral load at set point([@bb0305])2010European ancestry\
U.S.*RYR3*Susceptibility to atherosclerosis([@bb1065])2010European, African (African American or Afro-Caribbean), and Hispanic ancestry\
Canada, U.S., Australia*HLA-C*, *MICA*, *HLA-B*, *HCP5*, *PSORS1C3*HIV-1 viral load control([@bb0475])2011European ancestry\
U.S.*PARD3B*Progression to AIDS([@bb1165])2015European, African, Hispanic ancestry (NR)*ACKR1* for Neutrophil count in HIV-infection; *UGT1A*, *UGT1A1*, *UGT1A3*, *UGT1A4*, *UGT1A5*, *UGT1A6*, *UGT1A7*, *UGT1A8*, *UGT1A9*, *UGT1A10*, *MROH2A* for Total bilirubin levels in HIV-infectionMultiple phenotypes measured by standard clinical laboratory practice([@bb0865])2015European ancestry\
U.S., Australia, France, Netherlands*MICA*, *CCRL2*, *HLA-B*, *HLA-C*HIV-1 viral load at set point([@bb0825]) ***Human Papillomavirus (HPV)***2011European and Hispanic ancestry\
*Discovery:* Czech Republic, Hungary, Poland, Romania,Russian Federation, Slovakia\
*Replication:* Argentina, Brazil, Cuba*HLA-DQB1*HPV seroconversion([@bb0165])2013Asian ancestry\
*Discovery:* China\
*Replication:* China*EXOC1*, *HLA-DPB2*, *GSDMB*, rs9277952 (locus:6p21.32)HPV-related cervical carcer([@bb1055])2013European ancestry\
*Discovery:* Sweden\
*Replication:* Sweden*MICA*, *HLA-DRB1*, *HLA-DQA1*, *HLA*Susceptibility to cervical cancer.([@bb0170])2016European ancestry\
*Discovery:* Sweden\
*Replication:* Swedenrs73730372 (locus:6p21.32)Susceptibility to cervical cancer.([@bb0175]) ***Influenza A virus (H1N1)***2015European ancestry\
SpainSee [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}Susceptibility to influenza A (H1N1) infection and disease severity([@bb0365]) **Bacteria** ***Helicobacter pylori***2013European ancestry\
Germany and Netherlands*TLR-1*, *HSPA6/FCGR2A/BH. pylori* seroprevalence defined using anti--*H. pylori* serum IgG antibody titers([@bb0805]) ***Mycobacterium tuberculosis***2010African ancestry\
*Discovery:* Ghana, The Gambia\
*Replication:* Ghana and Malawirs4331426 (locus 18q11.2)Tuberculosis susceptibility([@bb1145])2012African, Asian and European ancestry\
*Discovery:* Ghana\
*Replication:* The Gambia, Indonesia and Russia*WT1*Tuberculosis susceptibility([@bb1150])2014African ancestry and other\
The Gambia, Ghana, Malawi, South Africa*SMOC1*, *WT1*Tuberculosis susceptibility([@bb0180])2015European and African ancestry\
*Discovery:* Russia\
*Replication:* Russia, The Gambia and Ghana*ASAP1*Tuberculosis susceptibility([@bb0230])2016[a](#tf0005){ref-type="table-fn"}African ancestry\
Uganda and Tanzania*IL-12*Tuberculosis resistance in HIV-positive individuals([@bb1085]) **Subgengival bacterial biofilm (e.g.: *Porphyromonas gingivalis*)**2010European ancestry\
*Discovery:* Germany\
*Replication:* Netherlands*GLT6D1*Periodontitis susceptibility([@bb1030])2016European ancestry\
*Discovery:* U.S.\
*Replication:* U.S. and Germany*CLEC19A*, *TRA*, *GGTA2P*, *TM9SF2*, *IFI16*, *RBMS3*, *C1QTNF7*, *TSNARE*, *HPVC1*, *SLC15A4*, *PKP2*, *SNRPN*Periodontal disease-related phenotypes([@bb0905])2017Hispanic ancestry, European and African (African-American and Afro-Caribbean) ancestry\
*Discovery:* Hispanics/Latinos America\
*Replication:* U.Srs149133391 (locus 1q42.2)Periodontitis susceptibility([@bb1025]) **Mouth carbohydrate-fermenting bacteria (e.g.: *Streptococcus mutans*)**2013European ancestry (NR)*AJAP1*, *LYZL2*Dental caries-related phenotypes([@bb1050])2014European ancestry\
U.S.*KPNA4* for Pit-and-Fissure cariesDental caries susceptibility([@bb1255])2016Hispanic/Latino ancestry\
U.S.*NAMPT*, *BMP7*Dental caries susceptibility([@bb0870]) ***Mycobacterium leprae***2009Asian ancestry\
*Discovery:* China\
*Replication:* China*RIPK2*, *TNFSF15*, *LACC1*, *NOD2*, *HLA-DR*, *CCDC122*Leprosy susceptiility and progression([@bb1260])2011Asian ancestry\
*Discovery:* China\
*Replication:* China*IL23R*, *RAB32*, *CYLD*Leprosy susceptiility([@bb1270])2015Asian ancestry\
*Discovery:* China\
*Replication:* China*IL23R*, *IL1RL1*, *IL12B*, *HLA-DRB1*, *RAB32*, *TNFSF15*, *NOD2*, *BATF3*, *CDH18*, *DEC1*, *EGR2*, *CCDC88B*, *CIITA*, *SIGLEC5*, *RIPK2*, *LACC1,* rs16948876 (locus 16q12.1)Leprosy susceptiility([@bb0700])2016Asian ancestry\
*Discovery:* China\
*Replication:* China*SYN2*, *BBS9*, *CTSB*, *MED30*Leprosy susceptiility([@bb1210]) ***Neisseria meningitidis***2010European ancestry\
*Discovery:* UK\
*Replication:* Austria, Netherlands, Spain*CFH*, *CFHR3*Susceptibility to meningococcal disease([@bb0240])2016European ancestry\
*Discovery:* Spain\
*Replication:* Spain, UK*CFH*Susceptibility to meningococcal disease([@bb0770]) ***Propionibacterium acnes***2014Asian ancestry\
*Discovery:* China\
*Replication:* China*DDB2*, gene cluster including *SELL*, *SELP* and *SELE*Severe acne susceptibility([@bb0435])2014European ancestry\
*Discovery:* UK\
*Replication:* UK*FST*, *TGFB2*, *OVOL1*Severe acne susceptibility([@bb0875]) ***Salmonella typhi***2014Asian ancestry\
*Discovery:* Vietnam\
*Replication:* Vietnam and Nepalese*HLA-DRB1*Enteric fever susceptibility([@bb0270]) ***Staphylococcus aureus***2015Hispanic ancestry\
Mexico*KAT2B* for intermittent carriage*S. aureus* nasal carriage([@bb0120])2016European ancestry\
U.S.*HLA-DRB1* for all *S. aureus* infectionsSusceptibility to *S. aureus* and to skin and soft tissue *S. aureus* infections (SSTIs)([@bb0250]) ***Streptococcus pneumoniae***2016African ancestry\
*Discovery:* Kenia\
*Replication:* KeniaAC00600.5 and AC011288.2 (two overlapping intergenic non-coding RNA genes)Pneumococcal bacteremia([@bb0550]) **Parasites*****Leishmania donovani/Leishmania infantum chagasi***2013Asian and Hispanic ancestry\
*Discovery:* India, Brazil\
*Replication:* India*HLA-DRB1-HLA-DQA1*Visceral leishmaniasis susceptibility([@bb0650]) ***Plasmodium falciparum***2009African ancestry\
*Discovery:* The Gambia\
*Replication:* The Gambia*HBB*Severe malaria susceptibility([@bb0495])2012African ancestry\
*Discovery:* The Gambia\
*Replication:* The Gambia and Ghana*HBB*, *ABO*, *ATP2B4*, *MARVELD3*Severe malaria susceptibility([@bb1155])2013African ancestry\
The Gambia, Kenya, Malawi*HBB*, *ABO*Severe malaria susceptibility([@bb0060])2015African ancestry\
*Discovery:* Kenya, Malawi, The Gambia\
*Replication:* Malawi, United Republic of Tanzania, Cameroon, Burkina Faso, The Gambia, Ghana, Mali*HBB*, *ABO*, *ATP2B4*, *FREM3/GYPE* regionSevere malaria susceptibility([@bb0730]) **Prion** **Prion (Creutzfeldt-Jakob disease)**2009European and Oceanian ancestry\
*Discovery:* UK\
*Replication:* UK and Papua New Guinea*PRNP*Susceptibility to variant CJD([@bb0835])2011European ancestry\
*Discovery:* UK\
*Replication:* France, UK*PRNP*, *MTMR7*, *NPAS2*Susceptibility to variant CJD([@bb1015])2015European ancestry\
*Discovery:* Germany, Netherlands, UK\
*Replication:* Australia, Austria, France, Germany, Netherlands, Italy, Spain*PRNP*, *GRM8*Susceptibility to sporadic CJD([@bb1020])  **GWAS for response to treatment for infectious diseases** **Viruses** ***Hepatitis C virus (HCV)***2009European, African (African American or Afro-Caribbean) and Hispanic ancestry (NR)*IFNL3/IFNL4* (European Ancestry)Response to antiviral treatment with pegylated interferon-alpha combined with ribavirin (pegIFNα/ribavirin)([@bb0375])2009Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*IFNL3/IFNL4*Response to antiviral treatment with (pegIFNα/ribavirin)([@bb1120])2009European ancestry\
*Discovery:* Australia\
*Replication:* Germany, Italy, UK, Australia*IFNL3*, *IFNL3/IFNL4*Response to antiviral treatment with (pegIFNα/ribavirin)([@bb1105])2010European ancestry\
Germany, Switzerland*IFNL2*, *IFNL3/IFNL4*, *IFNL1*Response to antiviral treatment with (pegIFNα/ribavirin)([@bb0990])2010European, African American and Hispanic ancestry\
U.S.*ITPA*Susceptibility to treatment-related anaemia([@bb0310])2010Asian ancestry\
*Discovery:* Japan\
*Replication:* Japan*ITPA*Susceptibility to treatment-related anaemia([@bb0895])2011Asian ancestry\
Taiwan, Japan*IFNL3/IFNL4*HCV treatment response([@bb0900])2011Asian ancestry\
*Discovery:* Japan\
*Replication*: NR*DDRGK1*, *ITPA* for Hb level and platelets countSusceptibility to pegIFNα-induced thrombocytopenia and to RBV-induced anaemia([@bb1125])2012European and African (African-American and Afro-Caribbean) and Hispanic ancestry\
U.S.*ITPA*Susceptibility to thrombocytopenia, neutropenia, and leukopenia related to pegIFNα treatment([@bb1130])2012Hispanic, European, and African (African American or Afro-Caribbean) (NR)*IFNL3/IFNL4*Lipid levels during and after HCV infection treatment and the interactions with sustained viral response (SVR)([@bb0195]) ***Human Immunodeficiency Virus (HIV)***2011Asian ancestry\
*Discovery:* Thailand\
*Replication:* Thailand*CCHCR1*Susceptibility to Nevirapine-induced rash([@bb0160])2014European, Hispanic, African (African American or Afro-Caribbean) ancestry\
U.S.*RSPO4* (hispanic - Grade ≥ 2); *IL2RA*, *CXCL12*, rs9501753 (locus:6p25.3), *PTPRB* (European ancestry -- Grade ≥ 3); *TANK*, *HDAC9,* rs801350 (locus:2q32.3), rs801378 (locus:2q32.3) (Hispanic - Grade ≥ 3)Susceptibility to peripheral neuropathy related to d4T/ddI-containing treatment([@bb0645])2015[a](#tf0005){ref-type="table-fn"}European, African, and Hispanic ancestry (NR)*SLC17A1*Plasma Tenofovir and creatinine clearance after TDF/emtricitabine containing regimens([@bb1215])  **GWAS for response to vaccine** **Viruses** **Measles, Mumps and Rubella vaccine**2014European ancestry\
U.S.*ACO1*, *PTPRD*Immune responses to rubella vaccination([@bb0545])2014European ancestry\
*Discovery:* Denmark\
*Replication:* Denmark*IFI44L*, rs1318653 (locus:1q32.2), *CD46*, *ANO3*, *SCN1A*, rs11105468 (locus:12q21.33), *SCN2A* for febrile seizures; *IFI44L*, *SCN1A*, *ANO3*, *CD46*, *CD34* for febrile seizures MMR vaccine-related; *ANO3*, *SCN1A* for febrile seizures MMR vaccine-unrelatedSusceptibility to general and measles, mumps and rubella (MMR) vaccine-related febrile seizures([@bb0295]) **Hepatitis B vaccine**2011Asian ancestry\
*Discovery:* Indonesia\
*Replication:* Indonesia*HLA-DR*, *HLA*, *HLA-DPB1*Immune response to HBV vaccine([@bb0955])2014Asian ancestry\
*Discovery:* China\
*Replication:* China*HLA-DRA*, *BTNL2*, *HLA-DRB1*, *C6orf10*Immune response to HBV vaccine([@bb0920]) **Smallpox vaccine**2012Hispanic, European and African (African-American and Afro-Caribbean) ancestry\
U.S.*MKX*, rs10503951 (locus: 8p12), *GPR158*, *ZHX2*, *SPIRE1* (African ancestry); *PCDH15*, *PRKCQ* (Hispanic ancestry)Immune response to smallpox vaccine([@bb0910])2012European and African (African-American and Afro-Caribbean) ancestry\
U.S.See [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}Cytokine responses to smallpox vaccine([@bb0540])[^2]

Sheer numbers, though, are not the only indicator of success. Important results were obtained by GWASs, both by identifying or refining associations in genes that were a priori expected to modulate infection susceptibility and by pointing out unexpected genes and pathways. Herein we discuss some issues associated with GWASs for infectious diseases, we review the most recent findings ensuing from these studies, and we provide a brief summary of selected GWASs in non-human mammals. [Table 1](#t0005){ref-type="table"} summarizes the results of human studies that detected at least one associated variant at genome-wide significance, whereas a list of all studies is available as [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}.

2. GWAS evolution {#s0010}
=================

GWASs rely on linkage disequilibrium between genotyped SNPs and causal variants (often ungenotyped). The number of variants on the SNP chips that are used for GWASs has increased sensibly since the development of this technology (from \~ 500,000 in the initial studies to \> 4,000,000 in the latest platforms). Moreover, the availability of an increasing number of fully sequenced genomes, together with the development of efficient imputation methods, has definitely expanded the power of GWASs to detect association with variants in the low range of the frequency spectrum (reviewed in ([@bb1200])). However, the overall power of a GWAS is also critically dependent on the sample size (reviewed in ([@bb1200]) and see below) and in most cases power remains low for variants with a frequency below 1% (reviewed in ([@bb1200])).

Notably, though, important developments have been achieved in terms of imputation of variants within the Major Histocompatibility Complex (MHC), with clear relevance for the investigation of infectious (and immuno-mediated) diseases. As recently reviewed elsewhere ([@bb0785]), the development of large reference panels (at least for Europeans and Asian populations) and the use of advanced imputation methods allowed the fine mapping of human leukocyte antigen (HLA) variants as susceptibility factors for some infectious diseases (e.g., HIV-1, HCV, and HBV infection) and many more autoimmune conditions ([@bb0785]).

Recently, an imputation algorithm for typing *KIR* (Killer-cell immunoglobulin-like receptor) gene copy number has also been developed and applied to data from European populations ([@bb1205]). However, *KIR* variability extends beyond copy number variation and next-generation sequencing technologies were proposed to allow high-resolution genotyping of *KIR* loci ([@bb0750]; [@bb0890]).

Finally, we mention that in 2009 a SNP chip (Immunochip) providing high coverage of immune-related genes, including *HLA* and *KIR* loci, came into use to fine-map and validate association signals for immune-mediated diseases ([@bb0210]). The application of the Immunochip in the field of infectious diseases has been very limited, with the notable exception of a study that investigated the genetic susceptibility to candidaemia and identified three risk variants ([@bb0620]).

3. Issues and caveats of GWASs for infectious diseases and related traits {#s0015}
=========================================================================

Some considerations apply to GWASs, whether they investigate infectious diseases or other conditions/traits. Although the sample size that is necessary to achieve an adequate statistical power depends on the genetic architecture of the analyzed trait, GWASs typically require large samples of individuals. This is because thousands (millions) of variants are simultaneously analyzed, making it difficult to disentangle true associations from false positives. Ideally, GWASs should enroll subject of shared and homogeneous ethnical ancestry, to avoid issues of population stratification, which can in turn produce spurious associations if not properly corrected. Moreover, phenotype heterogeneity ([@bb0075]), environmental confounders ([@bb0940]), as well as misclassification of cases and controls ([@bb0940]) have been shown to affect GWAS reliability and power. Some of these issues may be particularly relevant in the field of infectious diseases.

3.1. Sample size, population structure, and environmental confounders {#s0020}
---------------------------------------------------------------------

Large populations samples are often difficult to recruit in developing countries, due to limited resources, inadequate health facilities, and inefficient screening or diagnostic procedures. In these countries, however, the burden imposed by infectious diseases is highest ([@bb0510]; [@bb0715]). Also, some populations in developing areas have complex demographic histories. This is the case of African populations, that are genetically highly diverse and display a limited extension of linkage disequilibrium (LD) compared to non-Africans ([@bb0470]). For instance, one of the first GWASs for infectious diseases genotyped individuals in West Africa to identify susceptibility variants for severe malaria ([@bb0495]). The authors found considerable population stratification, which was corrected for using principal components analysis (PCA); signals of association at known malaria resistance loci (e.g. *HBB*) were difficult to retrieve due to weak LD between causal variants (e.g., HbS locus) and tag SNPs ([@bb0495]). Populations from South and Central America also display relevant population structure due to recent admixture ([@bb0125]). In a GWAS for visceral Leishmaniasis that included families from Brazil, ancestry differences and close relationships were efficiently corrected for using a linear mixed model ([@bb0650]). These models are an alternative to those based on PCA and rely on the incorporation of genetic relatedness between individuals directly in the statistical model (see ([@bb0280]; [@bb0425]; [@bb1240]) for reviews and comparison among different linear mixed model methods).

Another issue often related to population structure is that of environmental confounders ([@bb1195]). A well-known example in the field of non-communicable diseases relates to type 2 diabetes (T2D) susceptibility. Several studies for T2D indicated that the proportion of Native American genetic ancestry is associated with lower socioeconomic status in admixed Latino populations from North and South America ([@bb0150]; [@bb0335]; [@bb0765]; [@bb0930]). This effect is partially responsible for the generally higher incidence of T2D in Latinos. This exemplifies how the combined effect of genetic admixture and environmental factors has the potential to affect genetic associations. Indeed, poor socioeconomic conditions represent a risk factor for several infectious diseases ([@bb0055]; [@bb0105]; [@bb0345]; [@bb0800]; [@bb1040]). Thus, possible environmental confounders must be accounted for to avoid spurious associations or loss of statistical power. However, even in the presence of admixture and environmental confounders, associations can be retrieved with confidence. In a GWAS for tuberculosis (TB), Chimusa and coworkers analyzed admixed South African Coloured case-control cohorts ([@bb0180]). After accounting for population stratification and hidden relatedness, they replicated a previously reported association at the *WT1* gene ([@bb1150]) and performed trans-ethnic fine mapping of the association signals ([Table 1](#t0005){ref-type="table"}). The authors also found a positive correlation between San (an African ethnic group) ancestry proportion and TB status. Although complete information was available for a minority of individuals, no correlation was detected between socioeconomic status and ancestry components, leading the authors to suggest that the association between San ancestry and TB is not merely explained by differences in socioeconomic conditions ([@bb0180]).

3.2. Phenotype heterogeneity and case/control misclassification {#s0025}
---------------------------------------------------------------

Perhaps, the two most important points that characterize GWAS for infectious diseases compared to studies of non-communicable conditions are phenotypic heterogeneity and case-control misclassification. An important source of heterogeneity in GWASs for infectious diseases derives from genetic variation in the pathogen. One of the best known examples of how the genotype of the infectious agent can interact with the host genome refers to hepatitis C virus. Among the most significant findings of GWASs for infectious diseases was the identification in 2009--2010 of variants at the *IFNL3/IFNL4* loci (previously known as *IL28B*) that associate with spontaneous clearance of HCV infection and with response to interferon-α/ribavirin therapy ([@bb0375]; [@bb0990]; [@bb1105]; [@bb1120]) ([Table 1](#t0005){ref-type="table"}). This finding set the basis for a personalized treatment of HCV infection ([@bb0775]). However, the effect of the *IFNL3/IFNL4* variants on response to therapy is much stronger for patients infected with HCV genotypes 1 and 4 than for those infected with genotypes 2, 3, and 6 ([@bb0990]; [@bb0010]). Interestingly, interferon-α/ribavirin therapy is less effective for patients infected with genotypes 1 and 4 compared to the other genotypes ([@bb0285]). Thus, the prognostic value of the *IFNL3/IFNL4* variants is particularly relevant for patients infected with HCV genotypes that are poorly responsive to this treatment ([@bb0990]). These observations well exemplify how important the interaction of the host and pathogen genomes can be. Very recently, a genome-to-genome GWAS for HCV infection was performed, shedding more light into the interaction between human *IFNL4/IFNL3* variants and HCV genetic diversity ([@bb0025]) (see [Conclusions and perspectives](#s0090){ref-type="sec"} section).

Another notable example of how pathogen heterogeneity can interact with the host genotype refers to TB susceptibility. The human *Mycobacterium tuberculosis* complex (MTBC) consists of several major phylogenetic lineages whose names reflect their association with geographic areas ([@bb0115]). Candidate gene approaches have shown that host genetic variants can modulate susceptibility to TB caused by specific MTBC strains ([@bb0440]; [@bb0140]; [@bb0465]; [@bb0220]; [@bb1010]). For instance, a variant in *TLR2* was specifically associated with an increased risk of TB caused by the Beijing strain in a Vietnamese population, whereas two *SLC11A1* polymorphisms were found to be significantly more common in patients having tuberculosis caused by *M. tuberculosis* Beijing genotype strains than in patients carrying other genotypes ([@bb0140]; [@bb0220]). In populations from Ghana, an *IRGM* polymorphism was found to protect against disease caused by the Euro-American lineage ([@bb0465]), and polymorphisms in *ALOX5* were more strongly associated with TB caused by *M. africanum* West African 2 strain ([@bb0440]). Furthermore, associations of specific HLA class I alleles and disease caused by the Beijing, LAM, LCC and Quebec strains, as well as by the Euro-American or East Asian lineages, were found in a South African population ([@bb1010]).

Therefore, the genetic heterogeneity of MTBC may limit the reproducibility of GWASs, as different cohorts may indeed include patients with distinct TB epidemiologies and with TB caused by different *M. tuberculosis* strains.

Finally, misclassification of cases or controls is an issue for several association studies. In the case of infections, a major problem is the difficulty to assess exposure in the control population. For instance, it is sometimes impossible to determine whether individuals recruited as uninfected controls (e.g., based on serology) are seronegative because they were exposed but did not acquire the infection or because they were never or rarely exposed to the pathogen. Cases are also sometimes problematic to define. For instance, seropositivity can result from different routes of exposure, in turn associated with distinct probabilities of infection, and possibly modulated by diverse genetic factors. Moreover, the probability of infection may depend on several factors, including the genetic characteristics of the pathogen, the infectiousness of the transmitting individual, the general health status at the moment of exposure (this is clearly important for nosocomial infections, for instance).

Some of these issues are evident in a GWAS for susceptibility to HIV-1 infection. McLaren and coworkers combined information from multiple studies to obtain case-control cohorts of \> 6300 HIV-1 positive cases and 7200 general population HIV-1 negative controls ([@bb0820]). Cases derived from different studies and were infected via diverse routes (i.e., parenteral and sexual). No information was available for controls on HIV-1 exposure (e.g., at risk behavior or possible parenteral exposure). The study failed to detect association with HIV infection susceptibility other than the known *CCR5*Δ*32* variant. An association signal at the *HLA-B/HLA-C* genes was not confirmed after correcting for frailty (survival) bias ([@bb0820]). These results led to the conclusion that genetic variants that modulate HIV-1 acquisition are either rare or have small effects. However, as the authors note, the study design has a high potential for misclassification of both cases and controls ([@bb0820]). Indeed, cases may include subjects with low HIV-1 susceptibility who were infected due to very high exposure (e.g. via multiple blood transfusions), whereas controls may comprise subjects who never exposed themselves to the virus. Because studies on high-risk populations indicated that the proportion of subjects who are naturally resistant to HIV-1 is around 20% ([@bb0950]; [@bb0340]), it can be hypothesized that as many as 80% of controls would seroconvert if exposed. McLaren and coworkers estimated that the sample size of their GWAS provided 80% power for variants with 0.1 allele frequency and genotype relative risk (GRR) of 1.3. Their calculations also show that if \~ 30%, \~ 60%, or \~ 80% of cases were misclassified as controls, GRRs of 2, 3, or 4 would be respectively necessary to achieve the same power ([@bb0820]). In fact, the authors did detect association for the *CCR5*Δ*32* variant, indicating that polymorphisms with strong effect could be identified.

Another situation that may potentially lead to classification biases is reinfection. For instance, HCV reinfection is relatively common in high-risk groups (e.g., drug users) ([@bb0410]; [@bb0415]; [@bb0840]). If individuals are classified as persistently infected (chronic hepatitis C, CHC) based on viral loads measurements with relatively long intervals between tests, cases of clearance and reinfection can potentially be classified as persistent infections ([@bb0410]; [@bb0415]).

4. GWAS for viral infections {#s0030}
============================

4.1. HIV-1 {#s0035}
----------

In 2007, Fellay and coworkers performed the first GWAS for an infectious disease by investigating viral set-point in HIV-1 infection ([@bb0300]). This pilot study paved the way for several other GWASs. Indeed, the two signals detected within the *HLA* class I gene region were since confirmed by several studies ([@bb0305]; [@bb0670]; [@bb0475]) ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"} ). Additional GWASs focused on HIV-1 viral load, progression to AIDS, and susceptibility to infection ([Table 1](#t0005){ref-type="table"}). Their results have been extensively reviewed elsewhere ([@bb0740]).Fig. 2A. Schematic representation of adaptive and innate immunity pathways derived by the Reactome database (<http://www.reactome.org>/), version (v61) ([@bb0290]; [@bb0855]) (StableIDs: R-HSA-1280218 and R-HSA-168249).Black boxes show sub-pathway names and contributing genes (as derived from Reactome): only genes that carry genetic variants associated in GWASs are reported (see [Table 1](#t0005){ref-type="table"}). Color codes are shown in the legend. B. Schematic view of *HLA* class I and II loci. SNPs reported are associated to different traits related to pathogen (see [Table 1](#t0005){ref-type="table"}). Asterisk denote association to multiple pathogens. Color codes and genomic coordinates (hg19) are reported.Fig. 2

In recent years, GWASs for HIV-1 infection have also focused on understanding the host determinants of response to standard and experimental therapies, as well as on detecting variants responsible for susceptibility to treatment-related adverse effects ([Table 1](#t0005){ref-type="table"} and [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}) ([@bb0160]; [@bb0645]; [@bb1215]) ([Table 1](#t0005){ref-type="table"} and [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}).

4.2. HBV and HCV {#s0040}
----------------

Susceptibility to Hepatitis B and Hepatitits C viruses (HBV and HCV) was also extensively investigated in GWASs. Worldwide, chronic HBV or HCV infections represent the major causes of progressive liver disease, including liver cirrhosis (LC) and hepatocellular carcinoma (HCC) ([@bb1060]). HBV predominantly affects Southeast Asia and the East Pacific, where it reaches the highest prevalence in the world ([@bb0235]). It is thus not surprising that most GWASs performed to date genotyped individuals of Asian ancestry ([Table 1](#t0005){ref-type="table"}).

Genetic variations in HLA class II loci (*HLA-DP* and *HLA-DQ*) were significantly associated with susceptibility to chronic HBV infection and with HBV-related HCC ([@bb0810]; [@bb0520]; [@bb0885]; [@bb0500]; [@bb0505]; [@bb0660]; [@bb0570]; [@bb0450]; [@bb0155]; [@bb1115]) ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). Interestingly, host genetic variants in HLA class II genes were also found in association with hepatitis B vaccine response ([@bb0955]; [@bb0920]) ([Table 1](#t0005){ref-type="table"}).

In 2015, [@bb0505] performed the largest GWAS on a Chinese population including about 18,400 among cases (chronically-infected) and controls (seronegative). The study confirmed most of the previously reported associations in *HLA* class II genes and detected a new variant, rs1883832 in *CD40*, strongly associated with HBV chronic infection ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). rs1883832 influences *CD40* expression by affecting its translational efficiency ([@bb0490]). This association was confirmed, although not at genome-wide significant level, by a recent GWAS that analyzed chronically HBV-infected and spontaneously recovered subjects ([@bb0665]). In this study, the authors also identified an intergenic variant at 8p21.3 which represents an expression quantitative trait locus (eQTL) for the *INTS10* (integrator complex subunit 10) gene ([Table 1](#t0005){ref-type="table"}). Interestingly, the authors demonstrated that INTS10 suppresses HBV replication in liver cells via IRF3, and confirmed decreased INTS10 protein levels in plasma samples of chronically HBV-infected patients compared to subjects who spontaneously cleared infection ([@bb0665]).

Although these studies have opened up new horizons of research, analyses in populations of different ancestries are strictly required.

As mentioned above, a landmark discovery of GWASs for HCV infection was the identification of the *IFNL3/IFNL4* association. In addition to this locus, variants in HLA class II loci were also found to affect viral clearance and disease progression in chronic HCV infection ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). In addition, polymorphisms in apoptosis-related genes such as *RNF7*, *TULP1*, and *MERTK* were associated with liver fibrosis, whereas variants in *DEPDC5* and *MICA* were described as modulators of HCV-related hepatocellular carcinoma risk ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}).

4.3. Other widespread viral infections {#s0045}
--------------------------------------

The GWA strategy was also exploited to investigate other infections caused by viral pathogens with worldwide diffusion. These include Human Papillomavirus (HPV), Varicella Zooster virus (VZV), and Influenza A virus (IAV). Overall, these works unveiled a limited number of associations, sometimes as a consequence of small sample sizes and, consequently, modest statistical power.

In the case of HPV, most GWASs for susceptibility to infection and progression to cervical carcinoma confirmed associations to *HLA* class II genes ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). It should be noted, however, that some of these studies did not directly test HPV infection status, nor HPV type, making it difficult to determine which trait these associations refer to. An interesting observation is that polymorphisms in the *EXCO1* and *GSDMB* genes were associated with progression to cervical carcinoma ([@bb1055]) ([Table 1](#t0005){ref-type="table"}). *EXOC1* encodes a subunit of the exocyst complex involved in host innate immune response against DNA antigens ([@bb0480]), whereas *GSDMB* codes for the cancer-associated gasdermin-like protein, which is highly expressed in cervical cancer cells ([@bb1100]). These data suggest that both immunological and carcinogenic factors contribute to the risk of cervical cancer development.

With respect to VZV, a GWAS was performed to investigate risk factors for herpes zoster ([@bb0225]). Although the study had limited power and potential for control misclassification (e.g., individuals who never suffered from primary infection with VZV are not at risk of virus reactivation), a significant association was detected in the MHC region where the non-coding *HCP5* (HLA Complex P5) gene maps ([Table 1](#t0005){ref-type="table"}). Intriguingly, variants in this region were also associated with delayed progression to AIDS ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). *HCP5* derives from an endogenous retroviral element with sequence homology to the HIV-1 *pol* gene ([@bb0610]) and is primarily expressed in immune system cells ([@bb0690]). The function of this noncoding gene and its role (if any) in restricting viral infection remain to be determined. In fact, a functional study showed that HCP5 does not restrict HIV-1 infection in vitro ([@bb1245]), and refinement of the association signals within the *HLA* region indicated that the *HCP5* variant associated with HIV-1 control is indeed a marker for the HLA-B\*5701 allele ([@bb0305]; [@bb1160]). Likewise, *HCP5* variants that reached genome-wide significance in the VZV GWAS are in strong linkage disequilibrium with polymorphisms in the *HLA-B* gene region ([@bb0225]). It is thus possible that HCP5 has no effect on viral infection per se, but its variants tag specific *HLA* class I alleles/haplotypes.

As for IAV, a single study analyzed susceptibility to H1N1 virus infection ([@bb0365]). The authors found no genome-wide significant associations when severe influenza cases were compared to mild cases. Conversely, several SNPs reached the significance threshold when severe and mild cases were compared to the general population ([Table 1](#t0005){ref-type="table"} and [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}). However, these associations were obtained on very small samples of patients and controls, and no replication cohort was analyzed.

Finally, we draw attention to a recent GWAS that searched for genetic variants associated with diarrhoeal episodes in young children (1--2 years old) ([@bb0130]). All subjects were recruited in developed countries, where the majority of diarrhoeal episodes are caused by viral infections ([@bb1225]). Despite the potential issues of phenotype heterogeneity, a significant association was found for variants in *FUT2*, a gene encoding an alpha (1,2)-fucosyltransferase which participates in the production of histo-blood group antigens ([Table 1](#t0005){ref-type="table"}). In particular, the activity of FUT2 determines the expression of the ABO histo-blood group antigens on the gastrointestinal mucosa and in bodily secretions. Genetic diversity at the *FUT2* gene is maintained in human populations by balancing selection ([@bb0590]; [@bb0360]) and common *FUT2* null alleles are present in many populations ([@bb0535]; [@bb0585]; [@bb0685]). In homozygotes, these alleles determine the "non-secretor" phenotype. In the GWAS for diarrhoeal episodes, non-secretors were found to be at lower risk compared to secretors, a result in line with candidate-gene studies that associated the non-secretor status with protection from Rotavirus and Norovirus infections (which represent the leading causes of diarrhoeal disease in developed regions) ([@bb1225]; [@bb0680]; [@bb0135]; [@bb0460]; [@bb1140]). In line with the balancing selection scenario, however, candidate-gene studies associated the non-secretor status with higher risk for infection by different pathogens, including *Neisseria meningitidis*, *Streptococcus pneumoniae*, and *Candida* spp. ([@bb0085]; [@bb0090]; [@bb0145]). More recently, non-secretors were also found to be at higher risk to develop Crohn\'s disease ([@bb0350]; [@bb0815]). The molecular mechanism underlying the different predisposition to infection (and to Crohn\'s disease) of secretors and non-secretors most likely stems from the fact that both pathogenic and commensal microorganisms exploit oligosaccharides on the gastrointestinal mucosa for cytoadherence.

5. GWASs for bacterial infections {#s0050}
=================================

Studies on the genetic susceptibility to bacterial infections have investigated a wide variety of conditions, either resulting from specific infections (e.g., tuberculosis, pneumococcal bacteremia) or deriving from more heterogenous situations (e.g., periodontitis).

5.1. Specific infections {#s0055}
------------------------

GWASs for infections caused by *Neisseria meningitidis* ([@bb0240]; [@bb0770]), *Helicobacter pylori* ([@bb0805]), and *Mycobacterium leprae* ([@bb1260]), strongly pointed to a role for risk variants in genes of the innate immune system. For *H. pylori*, variants in *TLR1*, known to be essential for innate immunity against bacterial infection, were identified as strongly associated with seroprevalence ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). For *N. meningitidis*, two GWASs for meningitis and septicaemia identified variants in the *CFH* gene region ([@bb0240]; [@bb0770]) ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). C*FH* encodes complement factor H, a regulator of the complement system, which is bound by *N. meningitidis* to escape complement mediated killing ([@bb1035]).

In the case of leprosy, a single GWAS identified candidate susceptibility genes encoding proteins involved in innate immune response (*NOD2*, *TNFSF15*, and *RIPK2*) ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). Furthermore, in a GWAS for leprosy in the Chinese population, [@bb0700] found an overlap between their hits and those for autoimmunity/inflammatory diseases. For example, association with *CCDC88B*, identified in the leprosy GWAS ([Table 1](#t0005){ref-type="table"}), was also reported for primary biliary cirrhosis, sarcoidosis, and inflammatory bowel disease. Likewise, SNPs in *TNFSF15*, *LRRK2*, *IL18RAP/IL1RL1*, and *LACC1/CCDC122* represent susceptibility loci for both leprosy and Crohn\'s disease ([@bb0515]; [@bb0705]). This observation points to a shared immunological basis for infectious and inflammatory conditions ([@bb0700]). However, the study also showed that, whereas some shared loci (*RIPK2* and *LACC1/CCDC122*) had concordant effects on the risk for leprosy and for inflammatory/autoimmune diseases, some others (e.g., *IL18RAP/IL1RL1*) showed opposite or discordant risk effects. These findings suggest a complex scenario and a delicate balance between response to infection and autoimmunity/chronic inflammation ([@bb1075]).

As expected, genes of the adaptive immune system also turned out to harbor polymorphisms associated with susceptibility to infections. Variants in the MHC region were identified as risk factors for leprosy ([@bb1260]; [@bb0700]), *Staphylococcus aureus* infection ([@bb0250]), enteric fever caused by *Salmonella typhi* ([@bb0270]), and TB ([@bb1110]) ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). For this latter infection, several GWASs have been performed ([Table 1](#t0005){ref-type="table"} and Supplementary Table 1). The *WT1* association mentioned above was detected in two independent studies ([@bb0180]; [@bb1150]) and recently confirmed, although with a *p* value that did not reach genome-wide significance, in a family-based Moroccan discovery sample ([@bb0405]). The functional role played by *WT1*, a zinc-finger transcription factor, in TB susceptibility remains to be elucidated. An interesting possibility is that WT1 regulates cytokine expression or activation of the vitamin D receptor ([@bb0790]). Instead, the role played by *ASAP1*, a gene associated to TB in a Russian discovery cohort and replicated in African populations ([Table 1](#t0005){ref-type="table"}), is somehow clearer, as its protein product regulates dendritic cell migration ([@bb0230]). However, the signals in these genes showed very small effects (*WT1*) or failed to replicate (*ASAP1*) in a recent large TB study in the Icelandic population ([@bb1110]). This GWAS is a nice example of the power of imputation to enormously extend the number of analyzed variants. In fact, the authors used whole-genome sequencing of 2636 Icelanders to impute 28.3 million SNPs and insertions/deletions for \> 100,000 chip-typed individuals. These included subjects with pulmonary TB or infected with *M. tuberculosis*. This large-scale study detected association signals at MHC class II loci, which were validated in Russian and Croatian samples ([@bb1110]). As discussed above, the low reproducibility of associations across studies and populations may in part reflect local differences in circulating *M. tuberculosis* strains ([@bb1110]). Finally, we mention that variants nearby the *IL12B* gene, which encodes a subunit of interleukin 12, were recently associated to TB in African populations (from Tanzania and Uganda) ([@bb1085]). In this GWAS, the authors used an interesting approach by including in the study only HIV-1 positive individuals. The underlying rationale was that HIV-positive individuals who do not develop TB despite living in endemic areas should be genetically resistant and ideally suited to detect variants with strong effect. Indeed, the identified variant has a strong protective effect and may modulate *IL12B* expression ([@bb1085]). Although this signal has not been replicated yet, it is worth mentioning that loss-of-function mutations in *IL12B* cause mendelian susceptibility to mycobacterial disease, a rare condition characterized by the development of clinical symptoms following infection with weakly virulent mycobacteria ([@bb0945]).

A nice example of the ability of GWASs to identify unexpected associations was provided by a recent study on bacteremia caused by *Streptococcus pneumoniae* ([@bb0550]). By investigating a population of Kenyan children, Rautanen and coworkers identified an association peak located in the introns of two separate intergenic long non-coding RNAs (lncRNAs) annotated as *AC011288.2* and *AC006000.5* ([Table 1](#t0005){ref-type="table"}). Interestingly, the risk allele is relatively rare and restricted to populations of African ancestry, underscoring the relevance of population-specific variants in disease susceptibility. Assessing AC011288.2 RNA expression in leukocyte cell subsets, Rautanen and coworkers observed expression in neutrophils only. These cells are known to play a major role in pneumococcal clearance ([@bb0380]; [@bb0110]) and their count is an independent predictor of pneumococcal bacteremia in febrile children ([@bb0625]).

Thousands of lncRNA genes have been identified in the human genome ([@bb0030]) and growing evidence suggests that these molecules are involved in gene regulation in different cell-types and tissues, including the immune system ([@bb0030]). In 2013, using inter-crosses of mouse strains, Gomez and coworkers provided the first direct demonstration that a lncRNA (termed NeST) can modulate the outcome of infection ([@bb0385]). In particular, NeST was shown to be responsible for the persistence of Theiler\'s virus in the central nervous system, as well as for the clearance of *Salmonella* infection ([@bb0385]). These data suggest that additional lncRNA await identification as important players in immune response and infectious disease susceptibility.

5.2. Caries, periodontitis, and acne {#s0060}
------------------------------------

GWASs have also been applied to identify genetic determinants for very common human condition characterized by a strong interaction between environmental factors and the infecting/commensal bacteria. These include caries, which is caused by a wide array of carbohydrate-fermenting bacteria, ([@bb0630]), periodontitis, where an anaerobic bacterial biofilm participates in disease onset and progression ([@bb0630]), as well as acne, which is characterized by overgrowth of *Propionibacterium acnes*.

For dental caries a variety of loci were identified via GWASs. Studies in adults have yielded significant and "suggestive" associations within or near genes with roles in tooth development and host defense. Among these we mention *LYZL2*, encoding a bacteriolytic agent ([@bb1050]), *NAMPT*, which is involved in periodontal healing ([@bb0870]), and *BMP7*, a tooth development gene ([@bb0870]) ([Table 1](#t0005){ref-type="table"}). To date, none of the dental caries loci identified in GWASs in adults have been followed up in fine-mapping or replication studies. Importantly, given the complexity of caries etiology and the spectrum of contributing environmental factors, some authors speculated that the effects of some genetic variants may vary across different populations ([@bb0870]).

Although several GWASs were conducted for periodontitis, only few of them successfully identified implicated loci ([Table 1](#t0005){ref-type="table"} and [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}). Among them, the first GWAS for periodontitis ([@bb1030]) studied the aggressive type of disease and identified an association with a marker in the *GLT6D1* gene (encoding a glycosyltransferase) ([Table 1](#t0005){ref-type="table"}). Functional experiments suggested that reduced GATA3 binding affinity to the *GLT6D1* locus could be a component of the pathophysiology of periodontitis.

Subsequently, [@bb0905] used a promising approach that combined clinical phenotypes, biological intermediates of microbial burden, and measures of local inflammation to derive periodontal complex traits (PCTs). PCTs were carried forward to GWAS to identify PCT-associated loci among European American adult participants ([Table 1](#t0005){ref-type="table"}). The authors found several significant signals in loci that included genes involved in immune response and epithelial barrier function. However, candidate loci did not associate with current clinically determined periodontal disease categories upon replication.

Finally, GWASs were also used to find associations between genetic variants and severe acne susceptibility. The top signals identified in a Chinese population included a SNP within the promoter region of *DDB2* (a novel androgen receptor-interacting protein), as well as variants in *SELL/SELP/SELE* gene cluster ([Table 1](#t0005){ref-type="table"}). These selectins have important roles in regulating cutaneous inflammation ([@bb0435]) ([Fig. 2](#f0010){ref-type="fig"}). Instead, a GWAS conducted in a UK population identified genes linked to the TGFβ cell signaling pathway and to skin homeostasis, namely *OVOL1*, *FST* and *TGFB2* ([@bb0875]) ([Table 1](#t0005){ref-type="table"}).

6. GWASs for parasitic and prion diseases {#s0065}
=========================================

Parasitic infections, either caused by protozoa or by helminths, affect millions of people worldwide. For many parasitic diseases a heritable component has been demonstrated ([@bb1190]; [@bb1230]; [@bb0260]; [@bb0185]). However very few GWAS were conducted; their results are summarized in [Table 1](#t0005){ref-type="table"} and were reviewed elsewhere ([@bb0745]). We add herein that a recent GWAS explored the genetic susceptibility to malaria ([@bb0730]). Beyond confirming loci previously associated with severe malaria (*HBB*, *ABO*, *ATP2B4*) ([@bb0495]; [@bb1155]; [@bb0060]), this study identified additional variants on chromosome 4, between *FREM3* and a cluster of three glycophorin genes (*GYPE*, *GYPB*, and *GYPA*) ([Table 1](#t0005){ref-type="table"}). Glycophorins are sialoglycoproteins abundantly expressed on the erythrocyte membrane, where they play a functional role in invasion by *Plasmodium falciparum*. In a recent follow-up study, the authors identified an array of large copy number variants (CNVs) affecting the *GYPA* and *GYPB* genes ([@bb0640]). One of the identified CNVs (*DUP4*) is associated with resistance to severe malaria and explains the GWAS association signal ([@bb0730]).

The most common form of human prion disease in humans is Creutzfeldt-Jacob disease (CJD), which is classified as sporadic, acquired (iatrogenic or variant) or familial ([@bb0485]). Variants in *PRPN*, encoding the prion protein (PrP), are the best known genetic factor for susceptibility to CJD ([@bb0915]; [@bb0835]) ([Table 1](#t0005){ref-type="table"}). Nevertheless, associations to other genomic loci (MTMR7 and NPAS2 for variant CJD ([@bb1015]), GRM8 for sporadic CJD ([@bb1020])) were recently reported ([Table 1](#t0005){ref-type="table"}). *MTMR7* is specifically expressed in the central nervous system (CNS) and is involved in the phosphatidylinositol pathway, whereas *NPAS2* encodes a transcription factor implicated in neuronal function. Interestingly, the CJD susceptibility variant in *NPAS2* is in strong linkage disequilibrium with an SNP that regulates *PLCD3 in trans* ([@bb1015]). Because *PLCD3* encodes a catabolic enzyme of the phosphatidylinositol pathway, these data implicate this pathway in the susceptibility to variant CJD. As for *GRM8*, it encodes a member of the metabotropic glutamate receptor family. Other members of this family are involved in cellular signal transduction triggered by PrP ([@bb1175]). Thus, these data highlight the ability of GWASs to pinpoint molecular disease pathways.

7. GWAS in non-human mammals {#s0070}
============================

In comparison to human GWASs, association studies in domestic and laboratory animals offer advantages and disadvantages. Model animals, for instance, can be infected with a known dose of a genetically homogeneous pathogen, removing part of the variability associated to exposure routes and load in humans, as well as to the genetic heterogeneity of the infecting pathogen. Due to their peculiar demographic histories, both model and domestic animals often display extensive linkage disequilibrium and genetic homogeneity, at least within breeds or strains ([@bb0015]; [@bb0050]; [@bb0100]; [@bb0330]; [@bb0675]). This implies that GWASs can be carried out using much fewer markers and samples than required in human studies. The other side of the coin is that the often complex breeding strategies pose challenges related to population structure, cryptic relatedness, and extensive selective sweeps resulting from artificial selection. These factors need to be accurately corrected for, to avoid spurious associations and loss of statistical power. Popular methods to account for these effects include the use of PCA to explicitly model ancestry contributions ([@bb0965]) and the application of mixed model association methods (see ([@bb0425]; [@bb1240]; [@bb0330]) for review).

7.1. Mouse studies {#s0075}
------------------

In the field of mouse genetics, an important contribution to the mapping of complex traits came from the Collaborative Cross (CC), a collaborative effort aimed at providing the scientific community with a large panel of recombinant inbred mouse strains derived from genetically diverse founders ([@bb0190]; [@bb0795]). As founders are both classic inbred strains and wild-derived strains, the resulting mouse panel has higher genetic diversity and less population structure than other mouse-based resources. Within the CC framework, an ancestry-based approach was shown to be superior to marker-based methods for mapping QTLs ([@bb0040]). The utility of this approach in the field of infectious diseases was initially demonstrated by a genome-wide scan of incipient CC lines for susceptibility to *Aspergillus fumigatus*, a pathogen that recapitulates in mice the signs of human aspergillosis ([@bb0275]). The authors found that CC lines were heterogenous in terms of susceptibility to *A. fumigatus* infection, measured as survival days after infection, and the broad-sense heritability of this phenotype was 0.78. The genome-wide scan identified several QTLs, including one on chromosome 8 that contained the *Irf2* gene and another one on chromosome 10 covering cytokine (*Il20ra*, *Il22ra*) and interferon (*Ifngr1*) receptors ([@bb0275]). Incipient CC lines were then used to investigate the genetic susceptibility to IAV infection by recording several IAV-induced phenotypes, including virus replication, airway inflammation, weight loss, and pulmonary edema. Interestingly, a highly significant QTL on chromosome 16 (*HrI1*, *H*ost *r*esponse to *I*nfluenza), was identified ([@bb0320]). *HrI1* explained a considerable proportion of variation in several phenotypes and encompassed a genomic region where the *Mx1* gene maps. Because *Mx1* is a well-known IAV resistance gene ([@bb1095]), these findings provide a nice validation of the CC approach. Additional QTLs were mapped in the study and suggested that variants in *Il16* and/or *Nox4* (*HrI2*) modulate IAV-induced weight loss ([@bb0320]).

More recently, incipient CC lines were used to identify variants in *Trim55* associated with vascular cuffing after infection with a mouse adapted SARS-CoV strain ([@bb0400]) and QTLs for survival to *Klebsiella pneumoniae* infection ([@bb1185]). Importantly, CC mice have been used to create improved models of EBOV (*Ebola virus*) and WNV (*West Nile virus*) infection ([@bb0395]; [@bb0390]; [@bb0980]) and mouse populations showing diverse susceptibility to *M. tuberculosis* and *Pseudomonas aeruginosa* ([@bb0710]; [@bb1080]). These models await genome-wide scans to unveil the genetic determinants of infection susceptibility and severity.

7.2. Associations in dogs {#s0080}
-------------------------

Dogs have also proven useful models for the mapping of variants associated with infectious disease phenotypes. Dog breeds represent genetic isolates deriving from a few founder individuals and subject to strong artificial selection. Thus, breeds differ in several phenotypes. One of these is granulomatous colitis, which is caused by mucosally invasive *Escherichia coli* ([@bb1070]) and is described in boxers and bulldogs only ([@bb0215]; [@bb0735]). Within a larger project that assessed several traits and diseases, Hayward and coworkers performed a within-breed GWAS for granulomatous colitis and identified a strong association signal within a genomic region where several members of the *SLAM* (signaling lymphocyte activation molecule) gene family map ([@bb0430]). Interestingly, variants in the corresponding human genomic region have been associated with the susceptibility to Crohn\'s disease and ulcerative colitis ([@bb0350]; [@bb0705]; [@bb0065]). These data indicate that, both in dogs and in humans, genes within this region contribute to the maintenance of intestinal immune homeostasis in the presence of commensal or pathogenic bacteria.

7.3. GWASs in cattle and swine {#s0085}
------------------------------

In cows, GWASs have been widely applied to the field of infectious disease susceptibility. This is clearly motivated by the fact that infections cause a major economic burden in the cattle industry worldwide. In this context, GWASs and other genomic approaches are regarded as powerful strategies to develop breeding programs aimed at the generation of less susceptible livestock ([@bb0985]).

One of the most investigated traits was Johne\'s disease, a chronic gastrointestinal tract disease caused by *Mycobacterium avium* subspecies *paratuberculosis*. Several GWASs have been performed, mostly on naturally infected Holsteins and Jerseys (common breeds of dairy cattle): associated variants with small effect were identified in several analyses, but reproducibility among studies was extremely low, resulting in no confidently associated marker ([@bb0020]; [@bb0575]; [@bb0860]; [@bb0880]; [@bb0925]; [@bb1045]; [@bb0455]; [@bb1250]). Although the reasons for low across-study consistency are likely manifold and include different criteria to classify phenotypes and different statistical procedures, these results suggest that loci with a major effect on Johne\'s disease do not exist, at least in these breeds. Likewise, GWASs for susceptibility to bovine tuberculosis (caused by *Mycobacterium bovis*) yielded inconsistent results ([@bb0080]; [@bb0325]; [@bb0530]; [@bb0995]). Efforts to identify susceptibility alleles for other infectious diseases detected small-effect loci with poor replicability (reviewed in ([@bb0985])). To date, the greatest success was obtained for mastitis, which is commonly caused by bacterial infections; regions spanning the *DCK*, *SLC4A4*, and *EDN3* genes were detected in at least two studies ([@bb0525]; [@bb1005]; [@bb1090]; [@bb1235]). The functional role of these genes in mastitis and response to invading bacteria remains to be evaluated.

As is the case for cattle, infections represent major economic problems for the swine industry, with one viral pathogen, porcine reproductive and respiratory syndrome virus (PRRSV) accounting for substantial burden ([@bb0245]). Several GWASs for PRRSV susceptibility converged to identify a major locus on chromosome 4 (reviewed in ([@bb0245])). Fine mapping of the QTL region and a further functional genomics work identified a variant in the *GBP5* gene as likely causal ([@bb0245]). *GPB5* encodes an interferon-inducible guanosine triphosphatase which plays central roles in cell-intrinsic immunity. In humans, GBP5 acts as a restriction factor for HIV ([@bb0595]). For the purpose of swine breeding, this result is relevant as a variation at *GBP5* can be used for marker-assisted selection ([@bb0245]).

8. Conclusions and perspectives {#s0090}
===============================

As detailed above, GWASs for infectious diseases have provided important biological insight and, in some cases, the results have opened the way to personalized therapy ([@bb0095]). Huge gaps however remain, with a number of infections still not addressed by GWAS or similar approaches. For instance, hundreds of millions of people are infected by helminths ([@bb0445]), but no GWAS has investigated the genetic susceptibility to these parasites even though linkage studies provided evidence for several QTLs (reviewed in ([@bb0745])). Diarrhoea and meningitis also account for a heavy health burden, especially among children in developing countries (World Health Organization, <http://apps.who.int/gho/data/node.home>). Nonetheless, only two studies provided genome-wide scans for genetic associations to these conditions ([@bb0130]; [@bb0240]).

The general trend in the field of complex traits is to shift from GWAS to next-generation sequencing approaches (exome or genome sequencing). These latter provide several advantages over GWASs, which mainly derive from the possibility to identify rare or private risk variants. However, next-generation approaches require sample sizes even larger than GWASs ([@bb0035]; [@bb1280]) and the amount of phenotypic variance that is explained by rare penetrant variants may largely differ among traits. We consider that important knowledge on infectious disease susceptibility (and related traits) can be still gained by GWASs, especially for those conditions that have never been investigated using this approach.

A promising strategy for future GWASs will be to leverage information from the host\'s and pathogen\'s genomes. An interesting step forward in this direction came from a study that generated human genome-wide genotyping data of antiretroviral naive patients and almost complete HIV-1 genome sequences to systematically search for associations between host and virus variants (genome-to-genome scan) ([@bb0070]). The authors found strong associations between SNPs that tag *HLA* class I alleles and viral mutations in CTL (cytotoxic T lymphocyte) epitopes. These results clearly highlight the selective pressure imposed by the host immune system on the viral genome. No signals were detected outside the *HLA* class I loci and, on the viral genome, most selected sites were located in Gag and Nef. However, the majority of host-associated HIV-1 mutations were found to have no or little effect on viral load, suggesting that the virus can compensate for selective pressure with little fitness cost ([@bb0070]). More recently, [@bb0025] performed a genome-to-genome scans in patients chronically infected with HCV. As in the HIV-1 study, the authors found that the adaptive immune system exerts a selective pressure on the viral genome and drives the evolution of several positions across the HCV genome. Importantly, Ansari and coworkers also showed that the host genotype for a functional *IFNL4* variant modulates viral load only when the individuals are infected by a virus that carries a specific amino acid residue (serine) at position 2414 in the NS5A protein. This result clearly indicates that the host and viral genomes interact to determine the control of infection ([@bb0025]). The majority of patients recruited in the study were infected with genotype 3 and HCV is genetically heterogeneous, suggesting that other and possibly different interactions exist in patients infected by distinct HCV genotypes.

The functional polymorphism in *IFNL4* is a dinucleotide variant (ss469415590, TT/ΔG) and the effect of the "favorable" TT allele is recessive ([@bb0970]). This finding highlights the possible relevance of non-additive models in genetic associations. In particular, overodominant models may be particularly worth exploring in the field of infectious diseases. Remarkable examples of heterozygote advantage include those described for *HBB* and *G6PD* in relation to malaria. Heterozygosity at *HLA* genes has also been shown to protect against different infections (reviewed in ([@bb0975])), and the same is true for a common variant in *TIRAP*, with heterozygotes protected from malaria, invasive pneumococcal disease, bacteremia, and TB ([@bb0560]). Heterozygosity for a common polymorphism in *PRNP* also confers relative resistance to prion diseases ([@bb0830]). Overdominance causes multiple alleles to be maintained at a locus via balancing selection (reviewed in ([@bb0975])). A well-known example of this phenomenon is described above for the *FUT2* gene. The maintenance of multiple ABO histo-blood groups, which most likely resulted from the selective pressure exerted by different pathogens, is also due to balancing selection (reviewed in ([@bb0975])). Several works have indicated that targets of balancing selection in primate genomes have often evolved in response to pathogen-driven selective pressures ([@bb0635]; [@bb0315]; [@bb0045]; [@bb0355]), making overdominance an appealing model to test for resistance against infection. It should however be noted that the action of balancing selection does not necessarily imply that heterozygotes are protected against a specific diseases. Epitomal in this respect is the case of *FUT2* described above, as well as that of *ABO*: individuals with O histo-blood group are protected against severe malaria and cerebral malaria, but at higher risk of developing highly symptomatic cholera infection ([@bb0725]; [@bb0205]). Interestingly, large-scale studies that focused on specific variants involved in resistance to malaria ([@bb0725]; [@bb0200]) indicated that *G6PD* deficiency also results in different susceptibility phenotypes. Thus, the level of *G6PD* activity is associated with decreased risk of cerebral malaria, but with increased risk of severe malarial anaemia ([@bb0725]; [@bb0200]). Moreover, by using a Bayesian statistical framework that allows for heterogeneity of effects across populations and phenotypes, the authors showed that homozygotes for the derived allele of a variant in the 5′ upstream region of *CD40LG* have significantly reduced risk of severe malaria in The Gambia, but significantly increased risk in Kenya ([@bb0725]). Finally, a significant epistatic interaction was noted between the *HbC* variant and an SNP in *ATP2B4*, this latter encoding a major erythrocyte calcium channel ([@bb0725]). Overall, these results indicate that models of genetic resistance/susceptibility are often complex and that statistical methods that incorporate heterogeneity across populations and phenotypes may improve the power and reliability of GWASs.

For infectious diseases, a particular role may be played by interactions within *HLA* genes or among *HLA* variants and polymorphisms located outside the major histocompatibility complex. One example of this latter scenario relates to polymorphic variants in *HLA-C* and in the *MIR148A* gene (for microRNA-148a, mir-148a). [@bb0600] identified a polymorphism in the 3\'UTR of *HLA-C* which affects a miR-148a binding site and associates with HLA-C expression levels, as well as with HIV-1 control. More recently, the same authors showed that an insertion/deletion polymorphism flanking *MIR148A* modulates the expression of this microRNA and the level of HIV-1 control only in individuals carrying *HLA-C* alleles with an intact miR-148a binding site. The *MIR148A* variant has no effect on HIV-1 control among subjects who carry *HLA-C* alleles that do not bind miR-148A ([@bb0605]). Situations similar to the one described by Kulkarni and coworkers may be common and may be particularly important for *HLA* class I and *KIR* loci, as they biologically interact as binding partners. For instance, epistatic interactions among specific *KIR* and *HLA* loci have been shown to modulate the progression to AIDS ([@bb0420]; [@bb0370]; [@bb0755]), as well as the spontaneous ([@bb1135]; [@bb0555]) and therapy-induced clearance of HCV infection ([@bb0005]). Likewise, interactions within the MHC may be common and relevant in modulating infection-related phenotypes. Indeed, it was recently shown that non-additive and interaction effects within *HLA* loci are widespread and modulate the risk of different autoimmune diseases ([@bb0655]).

Taking these possibilities into account would certainly benefit the discovery of novel genetic effects modulating infection susceptibility or progression.

Finally, we note that, as recently highlighted, association studies have been dramatically skewed in terms of population inclusion: a 2016 survey of GWASs in the Catalog indicated that 81% of analyzed samples were of European ancestry and 14% of Asian ancestry ([@bb0960]). All other populations remained severely underrepresented. This trend is somehow attenuated in the studies we reviewed herein, as populations of Asian origin were included in \> 33% of studies (most of them on HBV, HCV, and mycobacterial infections), whereas 14% and 17% of GWASs analyzed at least one cohort of African or Hispanic/Latino ancestry, respectively. However, only two studies, both of them on prion diseases, included Pacific Islanders (from Papua New Guinea) and no GWAS recruited Australian aborigines or other native peoples. These percentages clearly highlight the need to extend GWASs analysis for infectious diseases to under-represented populations. This is required to ensure that the benefits of research are equally distributed, especially in light of the recent evidence of limited portability of GWAS results across populations ([@bb0760]).
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